Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Cannabis Bioscience International Holdings (CBIH) Change in Accured Expenses (2023 - 2025)

Cannabis Bioscience International Holdings' Change in Accured Expenses history spans 3 years, with the latest figure at $116116.0 for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 487.45% year-over-year to $116116.0; the TTM value through Nov 2025 reached $146182.0, up 210.59%, while the annual FY2025 figure was $97.0, N/A changed from the prior year.
  • Change in Accured Expenses for Q4 2025 was $116116.0 at Cannabis Bioscience International Holdings, up from $41719.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $116116.0 in Q4 2025 and bottomed at -$146228.0 in Q2 2024.
  • The 3-year median for Change in Accured Expenses is $33069.5 (2023), against an average of $16365.6.
  • The largest annual shift saw Change in Accured Expenses plummeted 698.8% in 2024 before it surged 487.45% in 2025.
  • A 3-year view of Change in Accured Expenses shows it stood at $43566.0 in 2023, then crashed by 168.79% to -$29969.0 in 2024, then soared by 487.45% to $116116.0 in 2025.
  • Per Business Quant, the three most recent readings for CBIH's Change in Accured Expenses are $116116.0 (Q4 2025), $41719.0 (Q2 2025), and -$11653.0 (Q1 2025).